Top priorities when applying QbD to biosimilar production

By charlottel / 15 August 2012 / 0 comments

Where do your current and future priorities lie in the biosimilar quality-by-design process?

We posed this question to the industry and the results are in;

the top priority when companies are looking to apply QbD to their biosimilar production is physiochemical characterisation
a close second are biological characterisations
and closing off the top three are preclinical concerns

What are your top priorities when it comes to QbD?

Interested in reading more on this topic? Take a look here:

For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D